QR Code

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies

Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs); acquired RAS mutation is sometimes observed at diseas...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Kozo Kataoka, Takeshi Yamada, Manabu Shiozawa, Naoto Takase, Kazuma Ito, Kentaro Yamazaki, Jun Watanabe, Toshihiro Kudo, Takeshi Suto, Toshihiko Matsumoto, Kohei Murata, Yusuke Suwa, Shogen Boku, Hisateru Yasui, Nobuhisa Matsuhashi, Atsuyuki Maeda, Kiichi Sugimoto, Yusuke Matsumoto, Mitsuru Yokota, Johannes Fredebohm, Keita Mori, Masataka Ikeda
Hōputu: Artigo
Reo:Inglês
I whakaputaina: The Japan Society of Coloproctology 2024-04-01
Rangatū:Journal of the Anus, Rectum and Colon
Ngā marau:
colorectal cancer
anti-egfr monoclonal antibody
ras-trace
ras-trace-2
ctdna
Urunga tuihono:https://www.jstage.jst.go.jp/article/jarc/8/2/8_2023-051/_pdf/-char/en
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite